a blue and white sign: A Lockheed Martin (LMT) Space Systems sign in Sunnyvale, California.

© Source: Ken Wolter / Shutterstock.com
A Lockheed Martin (LMT) Space Systems sign in Sunnyvale, California.

For years, investing in defense and aerospace paid off but that changed in the last year. Certification delays for the 737 MAX, made by Boeing (NYSE:BA), is clouding the airplane industry. It is also casting a shadow in well-run companies like Lockheed Martin (NYSE:LMT). The detail-oriented investor will look at the whole picture and realize that LMT stock, which spent much of the last few months in the $400 range, is on the verge of a break-out.

a close up of a sign: A Lockheed Martin (LMT) Space Systems sign in Sunnyvale, California.

© Provided by InvestorPlace
A Lockheed Martin (LMT) Space Systems sign in Sunnyvale, California.

Late last week, Lockheed management announced a few shareholder-friendly moves. This could help shares rebound from here.

Lockheed declared a $2.60 per share dividend, 20 cents higher than last quarter. Shareholders of record as of the close of business

Read More


The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 177 weeks of public selections as part of this ongoing live forward-testing research.

In 2017, the sample size began with 12 stocks, then 8 stocks in 2018, and at members’ request into 2020, I now generate 4 selections each week, 2 Dow 30 picks, and a separate article for monthly Growth & Dividend MDA breakout stocks. I now provide more than 6 different ways to beat the S&P 500 since my trading studies were made public.

Remarkably, the frequency streak of 10% gainers within a 4- or 5-day trading week remains at highly statistically significant levels above 80% not counting frequent multiple 10% gainers in a single week. More than 200 stocks have gained over 10% in a 5-day

Read More

As there is more and more re-open talk, some of the stocks that will likely benefit the most, are starting to move nicely. One of those is AptarGroup (ATR). The company has survived what they are calling the “Crisis Low Point” and looks to gradually recover over the second half of the year. AptarGroup has a modest dividend, but a very well managed one that can be relied on for a small piece of income. All of this while the stock begins to breakout of its recent tight trading range is a recipe for success.

Aptar Completes Acquisition of CSP Technologies

(Source: Google)

Who Are They?

Founded in 1992, AptarGroup operates in Asia, Europe, Latin America, and North America. They provide a range of packaging, dispensing, and sealing solutions. They break this down into three segments: Beauty + Home, Pharma, and Food + Beverage.

The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories,

Read More

On Friday, Coca-Cola (KO) announced a restructuring move, with as many as 4,000 employee positions cut, about 5% of its workforce. The stock market quickly voted its approval with a share price jump to 5-month highs. And, the sharp equity quote increase last week put the stock above its 200-day moving average for the first time since early March.

Image Source: Company Website

I was fortunate to buy Coca-Cola shares under $38 a share near the pandemic peak in fear during March. I posted a bullish story on the company around the same time here. Coke remains a top defensive play, especially if you are worried about the general market’s clear overvaluation and its logical drag on long-term returns going forward.

Dividend Too Good To Pass Up?

The primary argument for ownership is Coke’s high dividend yield vs. immediate beverage peers, other high profit margin, large-cap consumer staples, and the

Read More

HOUSTON – Tight end Darren Fells didn’t travel the most traditional route to the NFL, but by the looks of things, he has finally found a home with the Houston Texans. 

And at home-at home, where his wife, Lindsay, put her foot down when it came to COVID-19 – because, Fells jokes, he’s “the money-maker.”

Before that happened, though? A non-traditional route …

After spending the first few years of his professional sports career in Europe playing basketball, Fells finally made his way to the NFL in 2014, where he caught on with the Arizona Cardinals. 

Following a couple of stops in Cleveland and Detroit along the way, Fells eventually landed with the Texans where, with the help of Deshaun Watson at quarterback, 2019 was the best year of his career, catching 34 passes on 48 targets for 341 yards and seven touchdowns, all of which were career-highs.

“Here’s a

Read More

As precious metals continue to be a hot commodity, one of the ways to ride the wave is via Teck Resources (NYSE:TECK). Teck’s slide began much earlier than the rest of the market in early 2020. The stock peaked as the calendar turned and fell about 70% bottoming on March 18th. Since then, the stock has rallied almost 130%. The company remains undervalued with a well-managed balance sheet. The latest breakout is underway as the stock has broken above the 200-day moving average.

All numbers in CAD unless otherwise stated

What Does It Do?

Teck Resources is based out of Vancouver, Canada. The company researches, explores, develops, and produces natural resources in the Asia Pacific, the Americas, and Europe. Teck bases its business on multiple products that include steel-making coal; copper concentrates and refined copper cathodes; refined zinc and zinc concentrates; energy products, such as bitumen; and lead and

Read More

Johnson & Johnson  (JNJ) – Get Report is making some waves on Wednesday, acquiring Momenta Pharmaceuticals  (MNTA) – Get Report for $6.5 billion.

For its part, Momenta shares are up about 70% into the low-$52s, close to that $52.50 a share offer it received from J&J in the all-cash deal. 

Johnson & Johnson investors aren’t sweating the deal, either. The stock is up about 0.6% on the day, as some analysts have even made the case that the deal undervalues Momenta. 

The deal is expected to close in the second half of 2020 and will be used to bolster Johnson & Johnson’s autoimmune treatments. 

Remember, the company is coming off a top- and bottom-line earnings beat and raised its full-year outlook. Management also spoke favorably about its Covid-19 treatment.

All in all, the stock has been setting up attractively on the charts and the Momenta deal,

Read More